COVID-19 associated Sub-acute invasive pulmonary aspergillosis

• Published in: Mycoses 2021
• Main Authors: Swain, Satish, Ray, Animesh, Sarda, Radhika, Vyas, Surabhi, Singh, Gagandeep, Jorwal, Pankaj, Kodan, Parul, Khanna, Puneet, Xess, Immaculata, Sinha, Sanjeev, Wig, Naveet, Trikha, Anjan
• Format: Web Resource
• Language: English
• DOI: 10.1111/myc.13369

Background Though invasive pulmonary aspergillosis is a well known complication of COVID-19 pneumonia, indolent forms of aspergillosis have been rarely described. Methods We prospectively collected the clinico-radio-microbiological data of 10 patients of subacute invasive pulmonary aspergillosis (SAIA), who presented to our hospital with recent history of COVID-19 pneumonia along with cavitary lung disease, positive IgG (against Aspergillus) with or without positive respiratory samples for Aspergillus spp. Result The mean age of presentation of SAIA was 50.7 ±11.8 years. All the patients had recently recovered from severe COVID-19 illness with a mean duration of 29.2±12 days from COVID-19 positivity. Cough was the predominant symptom seen in 8/10 (80%) patients followed by haemoptysis. 7/10 (70%) patients were known diabetic. While serum galactomannan was positive in 5/9 patients (55.5%), fungal culture was positive in 2/7 patients (28.5%) and Polymerase chain reaction (PCR) for Aspergillus was positive in three patients. Eight (80%) patients presented with a single cavitary lesion; pseudo-aneurysm of pulmonary artery was seen in two patients and post COVID-19 changes were seen in all patients. All patients were treated with voriconazole, out of which four (40%) patients died during the follow-up period. Conclusion SAIA should be considered in the differential diagnosis of cavitating lung lesions in patients with recent history of COVID-19 in the background of steroid use with or without pre-existing diabetes